Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalability

Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from
a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing,
and analysis independently. During the run, the team encountered real-world conditions
- including pH variation and precipitation - which often cause enzyme-based processes
to fail. Despite this, the reaction continued to perform reliably and delivered strong
results, ultimately producing more than 500 grams of pharma-grade N-trans-
caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in
biomanufacturing without extensive purification steps. Additionally, the 99% conversion
of feedstock to end product highlights a level of efficiency that is challenging to achieve
and maintain in traditional biomanufacturing.

For Cayman Chemical, the outcome stood out based on prior experience as highlighted
by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical:
“I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical
component of what we do at Cayman. One common aspect of this work is a drop in
efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process
changes enough that it is considered a different process altogether.”

Westcott, continues, “During the experiment, from the first sample that we took the
analysis showed over a 99% conversion rate. There was some concern because I
thought that that maybe was a little bit too high. So, we decided to take a second
sample to see if it maintained a similar conversion rate. And we were a little surprised to
find out that we actually did achieve this 99% conversion in our first 100-fold scale up of
their process. That was very much an aha moment for us!”

“This pilot run is an important validation of our cell-free platform, demonstrating that it
performs reliably at scale and delivers strong results in the hands of an external partner.
The fact that this project reached pilot scale in less than a year underscores our ability
to move R&D at a disruptive pace - and just as importantly - it meaningfully reduces
platform execution risk by showing that our technology can be transferred and operated
successfully beyond our own labs.” states Chief Commercial Officer at eXoZymes,
Damien Perriman, and continues, “With more than 500 grams of pharma-grade NCT
now available from this run, we are actively engaging partners interested in evaluation,
formulation development, and potential commercialization.”

Formulation can be shipped to partners
With isolated high-purity NCT now produced at pilot scale, eXoZymes is actively
engaging with partners interested in formulation development, product validation, and
application-specific testing. The availability of high-purity material enables partners to
move beyond feasibility studies and into hands-on evaluation under relevant conditions.
Companies seeking to explore potential use cases, assess performance, or initiate
collaborative development discussions are invited to contact eXoZymes to request
samples and discuss next steps, right here:
https://exozymes.com/partners

About Cayman
Cayman Chemical helps make research possible by providing products and services to
scientists worldwide. Cayman’s collection includes high-quality biochemicals, assay kits,
antibodies, and proteins, empowering researchers to understand the biological
mechanisms of health and disease and develop new therapies. Cayman’s expert
scientists also offer custom synthesis, purification, and characterization of biochemicals
ranging from small drug-like heterocycles to complex biolipids, and fatty acids, and are
highly skilled in all aspects of assay and antibody development, protein expression,
crystallization, and structure determination. In addition, Cayman offers a wide range of
analytical services using LC-MS/MS, HPLC, GC, and many other techniques. Cayman
performs generic drug development and production in both Ann Arbor, Michigan and
Neratovice, Czech Republic.

Learn more at www.caymanchem.com

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a
historic first - offers the tools and insights to design, engineer, control and optimize
nature’s own natural processes to produce highly valuable natural products, via a
commercially scalable, sustainable, and abundant alternative: exozymes.
Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in
a bioreactor without using living cells. Exozymes can replace toxic petrochemical
processes and inefficient biochemical extraction with sustainable and scalable
biosolutions that transform abundant feedstock into valuable nutraceuticals and novel
medicines.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells,
exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial
success in the synthetic biology (SynBio) space, making exozymes the next generation
of biomanufacturing.

While the company, eXoZymes Inc., has introduced “exozymes” as a scientific concept,
they are not trademarking the concept, as they view it as a new nomenclature for wide
adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer
and be the market leader of.

Learn more at exozymes.com

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are
based on certain assumptions and describe the company’s future plans, strategies and
expectations, can generally be identified by the use of forward-looking terms such as
“believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,”
“project,” “estimate,” “anticipate,” “strategy,” “future,” “likely,” “potential,” or other
comparable terms, although not all forward-looking statements contain these identifying
words. All statements other than statements of historical facts included in this press
release regarding the company’s strategies, prospects, financial condition, operations,
costs, plans and objectives are forward-looking statements. Actual results could differ
materially for a variety of reasons. You should carefully consider the risks and
uncertainties described in the “Risk Factors” section of eXoZymes’ quarterly reports on
Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from
time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the forward-looking
statements. Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking statements, and
eXoZymes assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information, future events, or
otherwise. eXoZymes does not give any assurance that it will achieve its expectations.


eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135

press@exozymes.com

https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes